A Secondary Analysis of Imatinib Adherence Among Patients with Chronic Myeloid Leukemia
PublisherThe University of Arizona.
RightsCopyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.
AbstractBackground: Two recent studies have identified a strong association between treatment adherence and treatment response in patients with chronic myeloid leukemia (CML) treated with imatinib; and suggested a possible 7-10% tolerance margin for nonadherence before impaired treatment response is likely to occur. Objective: To determine at what percentage of dosing adherence of imatinib impaired treatment response (suboptimal response of incomplete cytogenetic response is likely to occur; and, conversely, at what percent of dosing adherence positive treatment response is likely to ensue CML patients.
Degree ProgramHonors College